Arsanilic acid

This is an old revision of this page, as edited by 70.35.222.158 (talk) at 22:55, 26 April 2006 (Added Drugbox, link to PubChem, Drugbank, CAS #. Current drug image is inaccurate, indicates Sodium where Hydrogen should bind.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Atoxyl® (p-aminophenyl-. arsenic acid) is the name of a toxic arsenic-containing (arsenical) drug used in the late 19th and early 20th centuries.

Arsanilic acid
File:Atoxyl.png
Clinical data
Pregnancy
category
  • ?
Routes of
administration
?
ATC code
Legal status
Legal status
  • ?
Pharmacokinetic data
Bioavailability?
Metabolism?
Elimination half-life?
Excretion?
Identifiers
  • (4-aminophenyl)arsonic acid
CAS Number
PubChem CID
DrugBank
CompTox Dashboard (EPA)
ECHA InfoCard100.002.432 Edit this at Wikidata
Chemical and physical data
FormulaC6H8AsNO3
Molar mass217.054 g/mol

Origins and uses

Atoxyl was first synthesized in 1859 by Antoine Béchamp by chemically reacting aniline and arsenic acid. Béchamp chose the name Atoxyl referring to the reduced toxicity of the resulting compound, compared to arsenic.

Atoxyl was initially used in medicine to treat simple skin diseases. In 1905, two British physicians, H.W. Thomas and A. Breinl, discovered that Atoxyl was active against the trypanosomes of sleeping sickness. The effect of atoxyl was however not very pronounced, and the necessary dosage was so high that its toxic side effects far outweighed the benefits. Atoxyl frequently caused blindness by damaging the optic nerve and other varied disorders.

Nevertheless, the discovery of atoxyl's activity against trypanosomes was the basis for a major advance by the bacteriologist Paul Ehrlich. Ehrlich believed the accepted formula for atoxyl at that time was incorrect. Ehrlich and an organic chemist, Alfred Bertheim, identified the correct structural formula. The correct formula suggested new ways that the atoxyl molecule could be modified, and a series of such derivatives were then synthesized for testing. Testing for anti-syphilitic activity was performed by Sahachiro Hata who worked in Ehrlich's lab. The result of this team effort was the discovery of the drug Salvarsan in 1909.